← All trials
NCT04880850
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 14, 2021
- Primary completion
- Mar 11, 2022
- Completion date
- May 20, 2022
- First posted
- May 11, 2021
- Last posted
- Dec 2, 2021
- Enrollment
- 578
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Novo NordiskLead sponsor
- Novo NordiskStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.